Chimerix: A Company Focused On Infectious Viral Diseases With Investment Characteristics Similar To Trius
- CMRX's brincidofovir is a novel anti-viral drug for preventing cytomegalovirus infections in hematopoeitc cell transplant patients.
- There is no drug approved for this indication.
- Cytomegalovirus infections can result in graft rejection, hospitilizations and death.
- I think that brincidofovir could gain approval in 2016 and my model projects potential sales of $800 million by 2021.